Transcend Therapeutics
Biotechnology, 220 5th Ave 17, New York, 10001, United States, 1-10 Employees
Phone Number: +12*********
Who is TRANSCEND THERAPEUTICS
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that ...
Read More
- Headquarters: 220 5th Ave 17, New York, New York, 10001, United States
- Date Founded: 2021
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from TRANSCEND THERAPEUTICS
Transcend Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Transcend Therapeutics
Answer: Transcend Therapeutics's headquarters are located at 220 5th Ave 17, New York, 10001, United States
Answer: Transcend Therapeutics's phone number is +12*********
Answer: Transcend Therapeutics's official website is https://transcendtherapeutics.com
Answer: Transcend Therapeutics's revenue is $1 Million to $5 Million
Answer: Transcend Therapeutics has 1-10 employees
Answer: Transcend Therapeutics is in Biotechnology
Answer: Transcend Therapeutics contact info: Phone number: +12********* Website: https://transcendtherapeutics.com
Answer: Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications. Transcends leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. Transcend has raised approximately $42M to date, and has been featured in the Wall Street Journal, Forbes, and Politico. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month